.png)
Why we focus on fighting antimicrobial resistance and how we do it.
AMR is a serious global health threat.
Antimicrobial resistance is a serious health crisis, responsible for over one million deaths each year. Projections suggest it could lead to 39 million deaths by 2050 and cause a 2-3.5% reduction in global GDP.
We need a continuous pipeline of new antibiotics coming to market to replace those which are no longer effective.
We can combat this rising threat on two main fronts:
-
Reduction of the rate at which bacteria (and other microbes) develop resistance.
-
Development of new antimicrobials that are effective against resistant infections.
Given the unclear drivers of resistance and the limited short-term impact of stewardship efforts, we focus on incentives for the development of new antibiotics.
Market incentives have failed to stimulate the needed innovation.
Due to a variety of challenges, market incentives have failed to stimulate the needed innovation.
This unsustainable market has driven most large pharmaceutical companies out of antimicrobial R&D, and much of the skills and expertise that were built up there is lost. Without urgent change, we are looking at the collapse of the antimicrobial pipeline within 4 to 8 years.
To address market failure,
a combination of push and pull incentives is needed.
R&D is only part of the solution, we need global access!
To ensure widespread access, ARMoR supports global access conditionalities, which tie access requirements to government and philanthropic funding for antimicrobial R&D.
We advocate for strategies such as pooled procurement and regulatory harmonisation to enhance global access.